Open Access
Subscription Access
Open Access
Subscription Access
Overview on Acquired Immunodeficiency Syndrome
Subscribe/Renew Journal
Acquired immunodeficiency syndrome (AIDS) causes an irreversible destruction of immune system. Currently, used drugs for treatment of HIV/AIDS act through inhibition of important viral enzymes such as reverse transcriptase, protease and/or integrase. Uncoating inhibitor has also been approved for treatment of AIDS with novel mode of action. However, it is now evident that the existing armoury of antiretroviral and even their triplet (cocktail) and/or quadruple (highly active antiretroviral therapy, HAART), will not lead to eradication of HIV infection. Therefore recently scientists have proposed different targets and treatment approaches towards the HIV/AIDS, which include entry inhibitors, transcription inhibitors, uncoating inhibitors, zinc finger inhibitors, gene therapy.
Keywords
AIDS, Life Cycle, Recent Targets.
Subscription
Login to verify subscription
User
Font Size
Information
- Kumar, Kotran, Robinns, Robbins Basic Pathology, 7, Elsevier, 147-155
- R. ananthnarayan, CK Jayaram paniker, Textbook of Microbiology, 7, orient longman, 583
- Kumar, Kotran, Robinns, Robbins Basic Pathology, 7, Elsevier, 148
- H.P. Rang, M. M. Dale, J.M. Ritter, P. K. More, Pharmacology, 5, Churchill livingstones, 686
- De Clercq E.; New anti-HIV agents and targets; Med Res Rev., 2002 Nov, 22(6), 531-65.
- Alcami J.; Introduction. A brief history of AIDS Enferm Infecc Microbiol Clin.; 2008 Oct, 26 Suppl 11, 1-4.
- Turpin JA., The next generation of HIV/AIDS drugs: novel and developmental anti-HIV drugs and targets, Expert Rev Anti Infect Ther., 2003 Jun, 1(1), 97-128.
- Prem Mohan, Anti-AIDS drug development: challenges and Strategies, pharmaceutical research, vol.9, No.6, 1992
- Reeves J. D., Piefer A. J., Emerging drug targets for antiretroviral therapy, Drugs, 2005, 65(13), 1747-66.
- Barbaro G., Scozzafava A., Mastrolorenzo A., Supuran C. T., Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome, Curr Pharm Des 2005, 11(14),1805-43.
- Schols D., HIV co-receptors as targets for antiviral therapy, Curr Top Med Chem 2004, 4(9), 883-93.
- Zinc finger inhibitor for HIV, Treat Rev, 1996 Dec, (No 23), 13
- De Clercq E., New anti-HIV agents and targets, Med Res Rev., 2002 Nov, 22(6), 531-65.
- De Clercq E., Novel compounds in preclinical/early clinical development for the treatment of HIV infection, Rev Med Virol., 2000 Jul-Aug,10(4), 255-77.
- Dunn S. J., Khan I. H., Chan U. A., Scearce R. L., Melara C. L., Paul A. M., Sharma V., Bih F.Y, Holzmayer T.A., Luciw P.A., Abo A., Identification of cell surface targets for HIV-1 therapeutics using genetic screens, Virology 2004 Apr 10, 321(2), 260-73.
- Tsygankov A. Y., Current developments in ani-HIV/AIDS therapy, Curr Opin Investig Drugs. 2009 Feb,10(2),137-49
- Barichievy S., Saayman S., Arbuthnot P., Weinberg M. S., RNA interference-based gene expression strategies aimed at sustained therapeutic inhibition of HIV, Curr Top Med Chem. 2009, 9(12),1065-78.
- Novel gene therapy for aids using mutated tRNAs, Reference: UCLA Case No. 1993-564, US Patent Number: 6,355,790
- Li J., Tang S., Hewlett I., Yang M., HIV-1 capsid protein and cyclophilin A as new targets for anti-AIDS therapeutic agents, Infect Disord Drug Targets. 2007 Sep, 7(3), 238-44.
- Parker C. G., Domaoal R. A., Anderson K. S., Spiegel D. A., An antibody-recruiting small molecule that targets HIV gp120, J Am Chem Soc. 2009 Nov 18,131(45), 16392-4
- Evgeni E. Gabev, Evgeni B. Gabev, Masha V. Bogoeva, Evgeni E. Gabev, Jr., Blocking of the polyphosphoinositide transmembrane signaling system is a novel and promising approaches for AIDS therapy, European journal of parenteral sciences 2002, 7(1), 3-11
Abstract Views: 197
PDF Views: 7